Robert Locklear: Sildenafil should be avoided in valve disease with residual pulmonary hypertension, study suggests

Monday, August 28, 2017

Sildenafil should be avoided in valve disease with residual pulmonary hypertension, study suggests

Sildenafil should not be used to treat residual hypertension in patients with valvular heart disease, according to new research. The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalization compared to placebo.